



Twist Bioscience Launches MRD Express with Rapid Turnaround Time

October 29, 2026

Turnaround time starting within one day

Twist panel enables researchers to combine the sensitivity of tumor-informed MRD detection with the speed and simplicity of tumor-naïve MRD detection when developing their tests

Twist capacity enables high-throughput production of custom MRD Express panels of up to 10,000 probes at the speed and scale needed by researchers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 29, 2026-- [Twist Bioscience Corporation](#) (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched [Twist MRD Express](#), custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research, biomarker discovery and assay development.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20261029639258/en/>



Twist MRD Express custom panels

when developing molecular residual disease (MRD) tests: tumor-informed, which incorporates a person's individual tumor variants in a personalized panel to identify recurrence, or tumor-naïve, which uses common biomarkers across a particular cancer indication to test multiple patients for these shared biomarkers. Tumor-informed MRD testing has higher sensitivity but is traditionally slower to develop due to personalization. With Twist MRD Express, cancer researchers can access personalized tumor-informed panels manufactured at scale and delivered on tumor-naïve timelines.

"To understand how cancer is responding at the molecular level, researchers need workflows that move as quickly as their questions demand," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. "With personalized Twist MRD Express panels we are eliminating the tradeoff researchers need to make between sensitivity and speed, enabled by enhancements to our manufacturing and automation processes within our existing high-throughput environment. Importantly, as MRD providers scale, their supply chains need to keep pace. Our platform is built to support that growth, giving customers confidence to plan beyond today's testing volumes."

About Twist MRD Express

[The Twist MRD Express](#) panel enables cancer researchers to pursue personalized, high specificity tumor-informed MRD testing without compromising on speed. The MRD Express panel can include up to 10,000 probes with industry-leading oligo quality and high uniformity. Panels incorporate modified bases, including locked nucleic acids (LNA), which can further improve sequencing sensitivity. With bioinformatics panel design support, ecommerce and touchless API ordering for the Twist MRD Express panel, Twist can enable customers' workflows at any stage. The Twist MRD Express panel is the latest evolution in Twist's robust offering of tools that enable the liquid biopsy and MRD research communities, including Twist's cfDNA Library Preparation Kit with TrueAmp™ Polymerase Mix and Twist cfDNA Pan-Cancer Reference Standard v2.

Twist's high-throughput silicon-based DNA synthesis platform is designed to help MRD providers build a supply chain that scales with their ambitions. By producing large numbers of customized probes in parallel, Twist can support growing demand as customers expand testing volumes and develop more comprehensive panels.

About Twist Bioscience Corporation

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on [LinkedIn](#) | [X](#) | [YouTube](#) | [Instagram](#) | [Bluesky](#)

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

Molecular residual disease (MRD) is the presence of a small amount of tumor-derived molecules, including genetic material that remain after cancer treatment. Researchers take one of two approaches

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding the expected performance, benefits and turnaround times of Twist MRD Express, and Twist's capacity to meet future demand. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Securities and Exchange Commission (SEC) on November 17, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20261029639258/en/>

FOR TWIST:

For Investors:

Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:

Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Source: Twist Bioscience Corporation